These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 14697902)

  • 1. Monoamine oxidase-B inhibition in Alzheimer's disease.
    Riederer P; Danielczyk W; Grünblatt E
    Neurotoxicology; 2004 Jan; 25(1-2):271-7. PubMed ID: 14697902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics.
    Gökhan-Kelekçi N; Yabanoğlu S; Küpeli E; Salgin U; Ozgen O; Uçar G; Yeşilada E; Kendi E; Yeşilada A; Bilgin AA
    Bioorg Med Chem; 2007 Sep; 15(17):5775-86. PubMed ID: 17611112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of MAO inhibitors: safety and future.
    Yamada M; Yasuhara H
    Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy.
    Zheng H; Youdim MB; Fridkin M
    ACS Chem Biol; 2010 Jun; 5(6):603-10. PubMed ID: 20455574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review).
    Cai Z
    Mol Med Rep; 2014 May; 9(5):1533-41. PubMed ID: 24626484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
    Hirvonen J; Kailajärvi M; Haltia T; Koskimies S; Någren K; Virsu P; Oikonen V; Sipilä H; Ruokoniemi P; Virtanen K; Scheinin M; Rinne JO
    Clin Pharmacol Ther; 2009 May; 85(5):506-12. PubMed ID: 19129751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
    Patil PO; Bari SB; Firke SD; Deshmukh PK; Donda ST; Patil DA
    Bioorg Med Chem; 2013 May; 21(9):2434-50. PubMed ID: 23517722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.
    Thomas T
    Neurobiol Aging; 2000; 21(2):343-8. PubMed ID: 10867219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
    Manzoor S; Hoda N
    Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
    J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases.
    Ucar G; Gokhan N; Yesilada A; Bilgin AA
    Neurosci Lett; 2005 Jul; 382(3):327-31. PubMed ID: 15925113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
    Sun Y; Chen J; Chen X; Huang L; Li X
    Bioorg Med Chem; 2013 Dec; 21(23):7406-17. PubMed ID: 24128814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening.
    Novaroli L; Reist M; Favre E; Carotti A; Catto M; Carrupt PA
    Bioorg Med Chem; 2005 Nov; 13(22):6212-7. PubMed ID: 16054369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can an adjuvant treatment or a pharmacologic prevention be common to several diseases? The case of those associated to neuromediator defects.
    Mathé G
    Biomed Pharmacother; 1995; 49(4):161-7. PubMed ID: 7669935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.